|
Cyplasin-SC™ Enters Next Phase of Efficacy Testing Edmonton, Alberta, October 5, 2007 CYPL: OTCBB, Frankfurt Exchange WKN:XYIA In recent third party validated cell based laboratory tests, Cyplasin-SC™ has shown a unique toxicity to many tumor cells, including human melanoma cells. However normal human cells are not affected by Cyplasin-SC at concentrations used to kill the tumor cells. These positive validated results allowed the Company to take Cyplasin-SC™ into dosing experiments in animals. The first question that was answered: what is the highest tolerated dosage and is it safe? A Contract Research Organization, AURIGON Life Sciences, Tutzing, Germany, performed the dose ranging studies. The experiments were devised such that other questions could also be answered: What is the highest dose of Cyplasin-SC™ to be tolerated when injected only once? What is the highest dose of Cyplasin-SC to be tolerated when injected repeatedly and what is the best time interval for the injections? What is the best mode of application either under the skin (subcutaneously), or into a vein (intravenously), or into the body cavity (intraperitoneally)? Positive results from these studies were obtained as all mice injected with Cyplasin-SC at concentrations toxic for the human melanoma cells survived and the results showed Cyplasin-SC™ was well tolerated by the organism. The best application form appears to be a subcutaneous application where Cyplasin-SC is injected under the skin. This will prove to be very advantageous for the next series of animal efficacy experiments where the mice will bear a human melanoma tumor growing on the surface of the animal and Cyplasin-SC™ will be injected in the vicinity of the tumor so as to exert its toxic effect as close to the cancer target as possible. Positive results from these experiments will then allow Cyplasin-SC to move to next step toxicology studies. About Melanoma Market statistics for skin cancer and melanoma show that melanoma currently affects more then 2.4 million people worldwide. In the US more than 62,000 new cases are reported every year, as fair-skinned and Sunbelt populations are at high risk for the disease. Australia has the highest rate of melanoma in the world among males and has the second highest rate in the world among females (Australia’s Health 2004, AIHW). Overall the world wide incidence has doubled over the past 20 years. About Cyplasin-SC™ Cyplasin-SC™ has demonstrated a selective ability to rapidly kill melanoma cancer cells while leaving normal non-cancerous cells untouched. Cyplasin is a protein originally discovered and isolated by Professor Petzelt from a marine organism, the sea hare (Aplysia punctata). The protein can now be manufactured as a recombinant protein which allows the company to develop the protein as a potential anticancer therapeutic product. Patents have been issued to the Company covering the Cyplasin protein. About Cyplasin Biomedical Ltd. (CBL) Founded in 2007 and headquartered in Edmonton, Alberta, Canada with a research laboratory close to Berlin, Germany, CBL is dedicated to bringing new anticancer therapeutics to the marketplace. The Company’s current goal is to develop and commercialize the anticancer properties of Cyplasin-SC ™ for skin cancers and melanomas. CBL is publicly traded (CYPL: OTCBB) Forward-Looking Statements This Press release includes and is based, inter alia, on forward-looking information and statements that are subject to risks and uncertainties that could cause actual results to differ. Such forward-looking information and statements are based without limitation, as statements regarding future drug development activities, anticipated products, or anticipated future revenues, benefits or advantages, and the future plans and objectives of the Company, that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, such as market acceptance of new products and services, changes in governmental regulations, interest rates, fluctuations in currency exchange rates and such other factors as may be discussed from time to time that may cause actual results or performance to differ materially from those currently anticipated in such statements. These expectations, estimates and projections are generally identifiable by statements containing words such as "expects", "believes", "estimates" or similar expressions. Although Cyplasin Biomedical Ltd., believes that its expectations and the information in this Press release were based upon reasonable assumptions at the time when they were made, it can give no assurance that those expectations will be achieved or that the actual results will be as set out in this Press release. Cyplasin Biomedical Ltd., makes no representation or warranty, expressed or implied, as to the accuracy, reliability or completeness of the information in the Press release, and neither Cyplasin Biomedical nor any of their directors, officers or employees will have any liability to you or any other persons resulting from your use of the information in the Press release. The OTCBB Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. Contact: Garth Likes |